Updates in multiple sclerosis and related disorders: highlights of the 57th Annual Meeting of the American Academy of Neurology, April 9-16, 2005, Miami Beach, FL.
Cook
Stuart D
SD
Department of Neurology and Neurosciences, New Jersey Medical School, University of Medicine and Dentistry of New Jersey, Newark, NJ, USA.
D000911:Antibodies, Monoclonal / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data; D006801:Humans; D007239:Infections / Q000150:complications / Q000276:immunology; D000068556:Interferon beta-1a; D016899:Interferon-beta / Q000009:adverse effects / Q000627:therapeutic use*; D007968:Leukoencephalopathy, Progressive Multifocal / Q000139:chemically induced / Q000276:immunology / Q000503:physiopathology; D008279:Magnetic Resonance Imaging / Q000639:trends; D009103:Multiple Sclerosis / Q000175:diagnosis* / Q000503:physiopathology* / Q000628:therapy; D000069442:Natalizumab; D009471:Neuromyelitis Optica / Q000175:diagnosis* / Q000503:physiopathology* / Q000628:therapy; D011237:Predictive Value of Tests
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069442:Natalizumab; D016899:Interferon-beta; D000068556:Interferon beta-1a